Literature DB >> 2294780

Histologic correlations with the clinical diagnosis of dysplastic nevus.

W C Black1, W C Hunt.   

Abstract

In melanoma kindreds the presence of dysplastic nevi correlates with greatly increased melanoma risk. The relative importance of sporadic, nonfamilial dysplastic nevi as a risk factor for melanoma is less certain. Although the clinical features of dysplastic nevi have been well described, the histologic basis for the diagnosis is not as firmly established. This study examines the degree of correspondence between the clinical and histopathologic diagnosis of dysplastic nevus. Histologic review of nevi with clinical features of dysplasia from 1,000 individuals demonstrated classic histologic features of dysplasia (as previously demonstrated in melanoma kindreds) in 54.7%. In 20.4% of patients, nevi displayed less convincing or only partially developed features of dysplasia. The remaining patients (24.9%) had nevi of other types. Correspondence between the clinical and histologic diagnosis of dysplasia was best for lesions from the trunk and in individuals beyond the age of 20 years. This study supports the validity of the dysplastic nevus as a clinical and pathologic entity.

Entities:  

Mesh:

Year:  1990        PMID: 2294780     DOI: 10.1097/00000478-199001000-00005

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  3 in total

Review 1.  The dysplastic naevus.

Authors:  W J Mooi
Journal:  J Clin Pathol       Date:  1997-09       Impact factor: 3.411

2.  Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours.

Authors:  D S Sanders; K Blessing; G A Hassan; R Bruton; J R Marsden; J Jankowski
Journal:  Mol Pathol       Date:  1999-06

3.  The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects.

Authors:  Keith Duffy; Douglas Grossman
Journal:  J Am Acad Dermatol       Date:  2012-07       Impact factor: 11.527

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.